Financial Performance - Total revenue for the three months ended March 31, 2022, was RMB 31,753,000, representing a 40.6% increase from RMB 22,553,000 in the same period of 2021[15] - Profit and total comprehensive income for the period was RMB 1,895,000, a decline of 38.3% compared to RMB 3,071,000 in the first quarter of 2021[15] - Earnings per share attributable to owners of the Company for the period was RMB 0.54, down from RMB 0.75 in the same period last year[13] - The profit attributable to owners of the Company for the three months ended 31 March 2022 was approximately RMB 2,155,000, compared to RMB 3,011,000 for the same period in 2021, indicating a decrease of about 28.4%[67] - The total profit and comprehensive income attributable to the owners of the company for the three months ended March 31, 2022, was approximately RMB 2.2 million, a decrease from RMB 3.0 million in the same period of 2021, primarily due to increased employee costs, operating expenses, and financing costs[104] Revenue Breakdown - Income from postpartum care services increased to RMB 11,869,000, up 26.1% from RMB 9,400,000 in the previous year[15] - Revenue from trading of medical equipment and consumables reached RMB 8,111,000 in Q1 2022, with no prior year comparison available[44] - Income from postpartum care services was RMB 11,869,000, an increase of 26.3% compared to RMB 9,400,000 in Q1 2021[44] - For the three months ended 31 March 2022, the Group's revenue increased by approximately RMB9.2 million or approximately 40.8% to approximately RMB31.8 million compared to RMB22.6 million for the same period in 2021[88] - Revenue from postpartum care services increased from approximately RMB9.4 million for the three months ended 31 March 2021 to approximately RMB11.9 million for the same period in 2022[88] - The income from trading of medical equipments and consumables was approximately RMB8.1 million for the three months ended 31 March 2022, compared to nil for the same period in 2021[88] Cost and Expenses - The Group's cost of sales was RMB 6,611,000, with no corresponding figure reported for the previous year[15] - Staff costs increased to RMB 10,136,000, up from RMB 7,597,000 in the same period of 2021[15] - The total staff costs for the three months ended 31 March 2022 amounted to RMB 11,259,000, an increase from RMB 8,054,000 in the same period of 2021, representing a growth of approximately 39.4%[65] - Other operating expenses increased from approximately RMB10.5 million for the three months ended 31 March 2021 to approximately RMB12.0 million for the three months ended 31 March 2022[95] - The other operating expenses for the postpartum care business rose from approximately RMB5.8 million for the three months ended 31 March 2021 to approximately RMB8.5 million for the three months ended 31 March 2022[95] - Finance costs increased from approximately RMB2.0 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022, primarily due to an increase in bank borrowing interest[99] Assets and Liabilities - The Group's total assets as of March 31, 2022, were RMB 306,217,000, compared to RMB 309,637,000 as of March 31, 2021[28] - Non-controlling interests at the end of the period were RMB 4,539,000, down from RMB 4,258,000 in the previous year[28] Shareholding and Governance - The number of issued ordinary shares as of 31 March 2022 was 400,000,000, with an issued share capital of HK$40,000,000[103] - The Company has confirmed that all Directors have complied with the Code of Conduct regarding securities transactions for the three months ended March 31, 2022[151] - The Company has adopted and complied with the Corporate Governance Code, except for a deviation from code provision A.2.1[141] - The roles of chairman and chief executive officer are held by Mr. Zhang Junshen, which the Board believes does not impair the balance of power and authority[149] - The Company maintains a high standard of corporate governance as essential for its continuous growth[141] Future Outlook and Strategy - The Group is optimistic about sustaining core business despite economic uncertainties due to the Covid-19 outbreak[83] - The Group plans to leverage its current client base to seek growth opportunities in the healthcare industry post-pandemic[83] - The Group aims to diversify its income streams through the development of trading medical equipments and consumables business[83] - Future outlook includes potential strategies for market expansion and product development to enhance revenue streams[104] Compliance and Audit - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the three months ended March 31, 2022, and confirmed compliance with applicable accounting standards and GEM Listing Rules[159] - The financial information in the report has not been audited, but adequate disclosures have been made according to legal requirements[159] - The Audit Committee is chaired by Mr. Chan Chi Fung Leo, who holds the necessary professional qualifications[158]
紫元元(08223) - 2022 Q1 - 季度财报